164 related articles for article (PubMed ID: 36444905)
1. Efficacy of Omaveloxolone in Friedreich's Ataxia: Delayed-Start Analysis of the MOXIe Extension.
Lynch DR; Chin MP; Boesch S; Delatycki MB; Giunti P; Goldsberry A; Hoyle JC; Mariotti C; Mathews KD; Nachbauer W; O'Grady M; Perlman S; Subramony SH; Wilmot G; Zesiewicz T; Meyer CJ
Mov Disord; 2023 Feb; 38(2):313-320. PubMed ID: 36444905
[TBL] [Abstract][Full Text] [Related]
2. Safety and Efficacy of Omaveloxolone in Friedreich Ataxia (MOXIe Study).
Lynch DR; Chin MP; Delatycki MB; Subramony SH; Corti M; Hoyle JC; Boesch S; Nachbauer W; Mariotti C; Mathews KD; Giunti P; Wilmot G; Zesiewicz T; Perlman S; Goldsberry A; O'Grady M; Meyer CJ
Ann Neurol; 2021 Feb; 89(2):212-225. PubMed ID: 33068037
[TBL] [Abstract][Full Text] [Related]
3. Propensity matched comparison of omaveloxolone treatment to Friedreich ataxia natural history data.
Lynch DR; Goldsberry A; Rummey C; Farmer J; Boesch S; Delatycki MB; Giunti P; Hoyle JC; Mariotti C; Mathews KD; Nachbauer W; Perlman S; Subramony SH; Wilmot G; Zesiewicz T; Weissfeld L; Meyer C
Ann Clin Transl Neurol; 2024 Jan; 11(1):4-16. PubMed ID: 37691319
[TBL] [Abstract][Full Text] [Related]
4. Safety, pharmacodynamics, and potential benefit of omaveloxolone in Friedreich ataxia.
Lynch DR; Farmer J; Hauser L; Blair IA; Wang QQ; Mesaros C; Snyder N; Boesch S; Chin M; Delatycki MB; Giunti P; Goldsberry A; Hoyle C; McBride MG; Nachbauer W; O'Grady M; Perlman S; Subramony SH; Wilmot GR; Zesiewicz T; Meyer C
Ann Clin Transl Neurol; 2019 Jan; 6(1):15-26. PubMed ID: 30656180
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and pharmacodynamics of the novel Nrf2 activator omaveloxolone in primates.
Reisman SA; Gahir SS; Lee CI; Proksch JW; Sakamoto M; Ward KW
Drug Des Devel Ther; 2019; 13():1259-1270. PubMed ID: 31118567
[TBL] [Abstract][Full Text] [Related]
6. Clinical evidence of interventions assessed in Friedreich ataxia: a systematic review.
Jain P; Badgujar L; Spoorendonk J; Buesch K
Ther Adv Rare Dis; 2022; 3():26330040221139872. PubMed ID: 37180421
[TBL] [Abstract][Full Text] [Related]
7. Omaveloxolone: First Approval.
Lee A
Drugs; 2023 Jun; 83(8):725-729. PubMed ID: 37155124
[TBL] [Abstract][Full Text] [Related]
8. Assessment of neurological efficacy of idebenone in pediatric patients with Friedreich's ataxia: data from a 6-month controlled study followed by a 12-month open-label extension study.
Meier T; Perlman SL; Rummey C; Coppard NJ; Lynch DR
J Neurol; 2012 Feb; 259(2):284-91. PubMed ID: 21779958
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of (+)-epicatechin in subjects with Friedreich's ataxia: A phase II, open-label, prospective study.
Qureshi MY; Patterson MC; Clark V; Johnson JN; Moutvic MA; Driscoll SW; Kemppainen JL; Huston J; Anderson JR; Badley AD; Tebben PJ; Wackel P; Oglesbee D; Glockner J; Schreiner G; Dugar S; Touchette JC; Gavrilova RH
J Inherit Metab Dis; 2021 Mar; 44(2):502-514. PubMed ID: 32677106
[TBL] [Abstract][Full Text] [Related]
10. Double-blind, randomized and controlled trial of EPI-743 in Friedreich's ataxia.
Zesiewicz T; Salemi JL; Perlman S; Sullivan KL; Shaw JD; Huang Y; Isaacs C; Gooch C; Lynch DR; Klein MB
Neurodegener Dis Manag; 2018 Aug; 8(4):233-242. PubMed ID: 30051753
[TBL] [Abstract][Full Text] [Related]
11. Randomized, clinical trial of RT001: Early signals of efficacy in Friedreich's ataxia.
Zesiewicz T; Heerinckx F; De Jager R; Omidvar O; Kilpatrick M; Shaw J; Shchepinov MS
Mov Disord; 2018 Jul; 33(6):1000-1005. PubMed ID: 29624723
[TBL] [Abstract][Full Text] [Related]
12. Omaveloxolone (Skyclarys
Dayalan Naidu S; Dinkova-Kostova AT
Trends Pharmacol Sci; 2023 Jun; 44(6):394-395. PubMed ID: 37142519
[No Abstract] [Full Text] [Related]
13. Patient-reported outcomes in Friedreich's ataxia after withdrawal from idebenone.
Cook A; Boesch S; Heck S; Brunt E; Klockgether T; Schöls L; Schulz A; Giunti P
Acta Neurol Scand; 2019 Jun; 139(6):533-539. PubMed ID: 30887496
[TBL] [Abstract][Full Text] [Related]
14. Evaluating mFARS in pediatric Friedreich's ataxia: Insights from the FACHILD study.
Rummey C; Perlman S; Subramony SH; Farmer J; Lynch DR
Ann Clin Transl Neurol; 2024 May; 11(5):1290-1300. PubMed ID: 38556905
[TBL] [Abstract][Full Text] [Related]
15. Biological and clinical characteristics of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS) cohort: a cross-sectional analysis of baseline data.
Reetz K; Dogan I; Costa AS; Dafotakis M; Fedosov K; Giunti P; Parkinson MH; Sweeney MG; Mariotti C; Panzeri M; Nanetti L; Arpa J; Sanz-Gallego I; Durr A; Charles P; Boesch S; Nachbauer W; Klopstock T; Karin I; Depondt C; vom Hagen JM; Schöls L; Giordano IA; Klockgether T; Bürk K; Pandolfo M; Schulz JB
Lancet Neurol; 2015 Feb; 14(2):174-82. PubMed ID: 25566998
[TBL] [Abstract][Full Text] [Related]
16. Randomized, double-blind, placebo-controlled study of interferon-
Lynch DR; Hauser L; McCormick A; Wells M; Dong YN; McCormack S; Schadt K; Perlman S; Subramony SH; Mathews KD; Brocht A; Ball J; Perdok R; Grahn A; Vescio T; Sherman JW; Farmer JM
Ann Clin Transl Neurol; 2019 Mar; 6(3):546-553. PubMed ID: 30911578
[TBL] [Abstract][Full Text] [Related]
17. Can rehabilitation improve the health and well-being in Friedreich's ataxia: a randomized controlled trial?
Milne SC; Corben LA; Roberts M; Murphy A; Tai G; Georgiou-Karistianis N; Yiu EM; Delatycki MB
Clin Rehabil; 2018 May; 32(5):630-643. PubMed ID: 29072092
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic and neurological effects and safety of high-dose nicotinamide in patients with Friedreich's ataxia: an exploratory, open-label, dose-escalation study.
Libri V; Yandim C; Athanasopoulos S; Loyse N; Natisvili T; Law PP; Chan PK; Mohammad T; Mauri M; Tam KT; Leiper J; Piper S; Ramesh A; Parkinson MH; Huson L; Giunti P; Festenstein R
Lancet; 2014 Aug; 384(9942):504-13. PubMed ID: 24794816
[TBL] [Abstract][Full Text] [Related]
19. Riluzole in patients with hereditary cerebellar ataxia: a randomised, double-blind, placebo-controlled trial.
Romano S; Coarelli G; Marcotulli C; Leonardi L; Piccolo F; Spadaro M; Frontali M; Ferraldeschi M; Vulpiani MC; Ponzelli F; Salvetti M; Orzi F; Petrucci A; Vanacore N; Casali C; Ristori G
Lancet Neurol; 2015 Oct; 14(10):985-91. PubMed ID: 26321318
[TBL] [Abstract][Full Text] [Related]
20. Omaveloxolone for the treatment of Friedreich ataxia: clinical trial results and practical considerations.
Lynch DR; Perlman S; Schadt K
Expert Rev Neurother; 2024 Mar; 24(3):251-258. PubMed ID: 38269532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
